NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $6.75 +0.06 (+0.90%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.73▼$7.1450-Day Range$5.91▼$8.1052-Week Range$2.09▼$14.84Volume2.17 million shsAverage Volume4.57 million shsMarket Capitalization$478.58 millionP/E RatioN/ADividend YieldN/APrice Target$18.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Altimmune alerts: Email Address Altimmune MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside178.5% Upside$18.80 Price TargetShort InterestBearish31.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.34) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector596th out of 936 stocksPharmaceutical Preparations Industry274th out of 436 stocks 4.3 Analyst's Opinion Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAltimmune has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Altimmune's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted31.89% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Altimmune has recently increased by 1.66%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALT. Previous Next 2.5 News and Social Media Coverage News SentimentAltimmune has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Altimmune this week, compared to 7 articles on an average week.Search InterestOnly 31 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat Follows25 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 257% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($1.34) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Altimmune's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Altimmune Stock (NASDAQ:ALT)Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More ALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALT Stock News HeadlinesJuly 9, 2024 | marketbeat.comEli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug (ALT)Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's beenJuly 6, 2024 | marketbeat.comMarketBeat Week in Review – 7/1 - 7/5 (ALT)The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings seasonJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 3, 2024 | marketbeat.comAltimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?Clinical-state biopharmaceutical company Altimmune Inc. NASDAQ: ALT focuses on developing peptide-based therapeutics for obesity and chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Their top candidate is a GLP-1/glucagon agonist called pemvidutide.July 3, 2024 | marketbeat.comAltimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseasesJuly 2, 2024 | marketbeat.comPfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes (ALT)Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and WegovyJuly 1, 2024 | marketbeat.comEli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market (ALT)Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.July 26 at 8:29 PM | finance.yahoo.comALT Jul 2024 0.500 call (ALT240726C00000500)July 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 25 at 7:30 AM | globenewswire.comAltimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of HepatologyJuly 25 at 2:12 AM | americanbankingnews.comComparing Altimmune (NASDAQ:ALT) and Adagene (NASDAQ:ADAG)July 24 at 1:42 PM | barrons.comAltimmune Inc.July 20, 2024 | ca.finance.yahoo.comALT Dec 2024 10.000 callJuly 20, 2024 | msn.comEli Lilly secures weight loss drug approval in China: How do rivals stack up?July 20, 2024 | fool.comCan These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?July 19, 2024 | americanbankingnews.comBrokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $18.80July 17, 2024 | investorplace.comForget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your PortfolioJuly 10, 2024 | fool.comBetter GLP-1 Biotech Stock: Altimmune vs. Viking TherapeuticsSee More Headlines Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$18.80 High Stock Price Target$25.00 Low Stock Price Target$12.00 Potential Upside/Downside+170.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,450,000.00 Net Margins-22,645.37% Pretax Margin-22,626.10% Return on Equity-46.96% Return on Assets-42.96% Debt Debt-to-Equity RatioN/A Current Ratio16.55 Quick Ratio16.55 Sales & Book Value Annual Sales$430,000.00 Price / Sales1,145.94 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.53Miscellaneous Outstanding Shares70,900,000Free Float67,995,000Market Cap$492.76 million OptionableOptionable Beta0.13 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Vipin K. Garg Ph.D. (Age 66)President, CEO & Director Comp: $986.14kDr. Matthew Scott Harris AGAF (Age 71)FCAP, M.D., MS, Chief Medical Officer Comp: $681.81kMr. Raymond M. Jordt M.B.A. (Age 51)Chief Business Officer Comp: $578.85kMr. Richard I. Eisenstadt M.B.A. (Age 66)Chief Financial Officer Comp: $619.69kMr. Bertrand Georges Ph.D.Chief Technology OfficerDr. M. Scot Roberts Ph.D. (Age 65)Chief Scientific Officer Comp: $599.25kMr. Tony Blandin B.S.Vice President of Quality & Compliance ManagementMr. Andrew Shutterly M.S.Corporate ControllerMore ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCKamadaNASDAQ:KMDAArbutus BiopharmaNASDAQ:ABUSBeyondSpringNASDAQ:BYSIMagenta TherapeuticsNASDAQ:MGTAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 54,154 shares on 7/26/2024Ownership: 0.344%Horizon Wealth Management LLCBought 10,000 shares on 7/22/2024Ownership: 0.014%Hennion & Walsh Asset Management Inc.Bought 129,276 shares on 7/20/2024Ownership: 0.182%SG Americas Securities LLCBought 214,968 shares on 7/12/2024Ownership: 0.359%Cetera Advisors LLCBought 9,977 shares on 5/24/2024Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $11.25 at the beginning of the year. Since then, ALT stock has decreased by 40.0% and is now trading at $6.75. View the best growth stocks for 2024 here. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.02. The business had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 22,645.37% and a negative trailing twelve-month return on equity of 46.96%. When did Altimmune's stock split? Shares of Altimmune reverse split before market open on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Altimmune's major shareholders? Altimmune's top institutional shareholders include SG Americas Securities LLC (0.36%), Bank of New York Mellon Corp (0.34%), Hennion & Walsh Asset Management Inc. (0.18%) and Horizon Wealth Management LLC (0.01%). Insiders that own company stock include Vipin K Garg, Matthew Scott Harris, David Drutz, Wayne Pisano, M Scot Roberts and Diane Jorkasky. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO) and Alliance Data Systems (ADS). This page (NASDAQ:ALT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
